Atrial natriuretic peptide protects against cisplatin-induced acute kidney injury

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 1, 2015, Pages 123-129

  Nojiri, Takashi ^a,b   Hosoda, Hiroshi ^a   Kimura, Toru ^a,b   Miura, Koichi ^a   Ishikane, Shin ^a   Tokudome, Takeshi ^a   Shintani, Yasushi ^b   Inoue, Masayoshi ^b   Miyazato, Mikiya ^a   Okumura, Meinoshin ^b   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute kidney injury; Atrial natriuretic peptide; Cisplatin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UREA; ANTINEOPLASTIC AGENT; AUTACOID; CCL2 PROTEIN, MOUSE; DRUG IMPLANT; ICAM1 PROTEIN, MOUSE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTECTIVE AGENT;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; IMMUNOBLOTTING; KIDNEY FUNCTION; KIDNEY TUBULE NECROSIS; MICROALBUMINURIA; MORPHOLOGY; MOUSE; NEPHROTOXICITY; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG IMPLANT; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KIDNEY; METABOLISM; NECROSIS; PATHOLOGY; RANDOMIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATRIAL NATRIURETIC FACTOR; CHEMOKINE CCL2; CISPLATIN; DRUG IMPLANTS; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; MICE, INBRED C57BL; NECROSIS; PROTECTIVE AGENTS; RANDOM ALLOCATION;

EID: 84925232182     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2624-4     Document Type: Article

References (17)

1. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007
2. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115-124
3. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 6:903-909
4. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318-328
5. Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata K, Sonoda R, Ban T, Yasue H, Imura H (1987) Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 76:115-124
6. Totsune K, Takahashi K, Murakami O, Satoh F, Sone M, Saito T, Sasano H, Mouri T, Abe K (1994) Natriuretic peptides in the human kidney. Hypertension 24:758-762
7. Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H (2009) Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept 154:44-53
8. Rosón MI, Toblli JE, Della Penna SL, Gorzalczany S, Pandolfo M, Cavallero S, Fernández BE (2006) Renal protective role of atrial natriuretic peptide in acute sodium overload-induced inflammatory response. Am J Nephrol 26:590-601
9. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Morita Y, Numaguchi Y, Okumura K, Murohara T (2009) Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 53:1040-1046
10. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Kimura H, Shiono M, Takayama T, Hirayama A (2011) Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol 58:897-903
11. Nojiri T, Hosoda H, Tokudome T, Miura K, Ishikane S, Kimura T, Shintani Y, Inoue M, Sawabata N, Miyazato M, Okumura M, Kangawa K (2014) Atrial natriuretic peptide inhibits lipopolysaccharide-induced acute lung injury. Pulm Pharmacol Ther 29:24-30
12. Wolf G, Thaiss F, Schoeppe W, Stahl RA (1992) Angiotensin II-induced proliferation of cultured murine mesangial cells: inhibitory role of atrial natriuretic peptide. J Am Soc Nephrol 3:1270-1278
13. Pandey KN, Nguyen HT, Li M, Boyle JW (2000) Natriuretic peptide receptor-A negatively regulates mitogen-activated protein kinase and proliferation of mesangial cells: role of cGMP-dependent protein kinase. Biochem Biophys Res Commun 271:374-379
14. Mori Y, Kamada T, Ochiai R (2014) Reduction in the incidence of acute kidney injury after aortic arch surgery with low-dose atrial natriuretic peptide: a randomised controlled trial. Eur J Anaesthesiol 31:381-387
15. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, Genter FC, Kurnik BR, Conger JD, Sayegh MH (1997) Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 336:828-834
16. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S (2007) Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370:1483-1493
17. Maimaitiyiming H, Li Y, Cui W, Tong X, Norman H, Qi X, Wang S (2013) Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria function. Am J Physiol Renal Physiol 305:F881-F890